mTOR (mechanistic target of rapamycin) inhibitors represent a promising therapeutic approach for neurodegenerative diseases by modulating autophagy, cellular metabolism, and protein synthesis pathways. The primary compounds in this class include rapamycin (sirolimus), everolimus (RAD001), and temsirolimus (CCI-779).
The mTOR pathway is a central regulator of cell growth, metabolism, and survival. It exists in two distinct complexes:
mTOR inhibition activates autophagy, a cellular process that clears damaged organelles, protein aggregates, and pathogens. This is particularly relevant for neurodegenerative diseases where toxic protein aggregates (amyloid-beta, tau, alpha-synuclein) accumulate[1].
| Compound | Condition | Phase | Trial ID |
|---|---|---|---|
| Rapamycin | Alzheimer's Disease | Phase 2 | NCT04629495 |
| Everolimus | Parkinson's Disease | Phase 1 | NCT05538472 |
| Rapamycin | ALS | Phase 1/2 | NCT04895566 |
Rubinsztein DC et al. Nature. 2015;521(7553):185-194. 2015. ↩︎
Gao J et al. Cell Death Dis. 2020;11(8):678. 2020. ↩︎
Caccamo A et al. J Neurosci. 2010;30(29):9718-9730. 2010. ↩︎
Wang Y et al. Mol Neurodegener. 2022;17(1):15. 2022. ↩︎
Liu K et al. Neurobiol Dis. 2018;109(Pt A):213-225. 2018. ↩︎
Wu Y et al. J Neurosci. 2019;39(27):5304-5318. 2019. ↩︎
Liu Z et al. Nat Commun. 2021;12(1):2975. 2021. ↩︎
Zhang X et al. J Clin Invest. 2019;129(10):4375-4390. 2019. ↩︎
Barmada SJ et al. J Clin Invest. 2014;124(8):3523-3538. 2014. ↩︎
Pagan F et al. Neurology. 2022;99(8):e791-e801. 2022. ↩︎
Jain S et al. Clin Pharmacol Ther. 2019;106(4):796-806. 2019. ↩︎
Sanchez-Ramos J et al. Pharmacol Res. 2021;168:105582. 2021. ↩︎